{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:04Z","timestamp":1791357244629,"version":"4.3.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,1,28]],"date-time":"2013-01-28T00:00:00Z","timestamp":1359331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,1,28]],"date-time":"2013-01-28T00:00:00Z","timestamp":1359331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s12325-013-0006-7","type":"journal-article","created":{"date-parts":[[2013,1,29]],"date-time":"2013-01-29T18:18:38Z","timestamp":1359483518000},"page":"114-126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Cariprazine in Schizophrenia: Clinical Efficacy, Tolerability, and Place in Therapy"],"prefix":"10.1007","volume":"30","author":[{"given":"Leslie","family":"Citrome","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,28]]},"reference":[{"key":"6_CR1","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1517\/14656560903061309","volume":"10","author":"J Volavka","year":"2009","unstructured":"Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10:1917\u20131928.","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl.1","key":"6_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1092852912000727","volume":"17","author":"L Citrome","year":"2012","unstructured":"Citrome L. Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia. CNS Spectr. 2012;17(Suppl. 1):1\u20139.","journal-title":"CNS Spectr"},{"key":"6_CR3","unstructured":"American Psychiatric Association. New Research Abstracts. 161st Annual Meeting of the American Psychiatric Association; May 3\u20138, 2008; Washington, DC."},{"key":"6_CR4","unstructured":"American Psychiatric Association. New Research Abstracts. 162nd Annual Meeting of the American Psychiatric Association; May 16\u201321, 2009; San Francisco, CA."},{"key":"6_CR5","unstructured":"American Psychiatric Association. New Research Abstracts. 163rd Annual Meeting of the American Psychiatric Association; May 22\u201326, 2010; New Orleans, LA."},{"key":"6_CR6","unstructured":"American Psychiatric Association. New Research Abstracts. 164th Annual Meeting of American Psychiatric Association; May 14\u201318, 2011; Honolulu, HI."},{"key":"6_CR7","unstructured":"American Psychiatric Association. New Research Abstracts. 165th Annual Meeting of the American Psychiatric Association; May 5\u20139, 2012; Philadelphia, PA."},{"key":"6_CR8","unstructured":"American Psychiatric Association. Syllabus and Proceedings Summary. 60th Institute on Psychiatric Services; October 2\u20135, 2008; Chicago, IL."},{"key":"6_CR9","unstructured":"American Psychiatric Association. Syllabus and Proceedings Summary. 61st Institute on Psychiatric Services; October 8\u201311, 2009; New York, NY."},{"key":"6_CR10","unstructured":"American Psychiatric Association. Syllabus and Proceedings Summary. 62nd Institute on Psychiatric Services; October 14\u201317, 2010; Boston, MA."},{"key":"6_CR11","unstructured":"American Psychiatric Association. Syllabus and Proceedings Summary. 63rd Institute on Psychiatric Services; October 27\u201330, 2011; San Francisco, CA."},{"key":"6_CR12","unstructured":"American Psychiatric Association. Syllabus and Proceedings Summary. 64th Institute on Psychiatric Services; October 4\u20137, 2012; New York, NY."},{"key":"6_CR13","unstructured":"National Institute of Mental Health and American Society of Clinical Psychopharmacology. Poster Abstracts. 48th Annual NCDEU Meeting; May 27\u201330, 2008; Phoenix, AZ."},{"key":"6_CR14","unstructured":"National Institute of Mental Health and American Society of Clinical Psychopharmacology. Poster Abstracts. 49th Annual NCDEU Meeting; June 29\u2013July 2, 2009; Hollywood, FL."},{"key":"6_CR15","unstructured":"National Institute of Mental Health and American Society of Clinical Psychopharmacology. Poster Abstracts. 50th Annual NCDEU Meeting; June 14\u201317, 2010; Boca Raton, FL."},{"key":"6_CR16","unstructured":"American Society of Clinical Psychopharmacology. Poster Abstracts. 51st Annual NCDEU Meeting; June 14\u201317, 2011; Boca Raton, FL."},{"key":"6_CR17","unstructured":"American Society of Clinical Psychopharmacology. Poster Abstracts. 52nd Annual NCDEU Meeting; May 29\u2013June 1, 2012; Phoenix, AZ."},{"key":"6_CR18","unstructured":"American College of Neuropsychopharmacology. 47th Annual Meeting; December 7\u201311, 2008; Scotsdale, AZ."},{"key":"6_CR19","unstructured":"American College of Neuropsychopharmacology. 48th Annual Meeting; December 6\u201310, 2009; Hollywood, FL."},{"key":"6_CR20","unstructured":"American College of Neuropsychopharmacology. 49th Annual Meeting; December 5\u20139, 2010; Miami Beach, FL."},{"key":"6_CR21","unstructured":"American College of Neuropsychopharmacology. 50th Annual Meeting; December 4\u20138, 2011; Waikoloa Beach, HI."},{"key":"6_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12325-013-0004-9","volume":"30","author":"L Citrome","year":"2013","unstructured":"Citrome L. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013;30:102\u2013113.","journal-title":"Adv Ther"},{"key":"6_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1517\/17425255.2013.759211","volume":"9","author":"L Citrome","year":"2013","unstructured":"Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. Expert Opin Drug Metab Toxicol. 2013;9:193\u2013206.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"6_CR24","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1124\/jpet.109.160432","volume":"333","author":"B Kiss","year":"2010","unstructured":"Kiss B, Horv\u00e1th A, N\u00e9methy Z, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010;333:328\u2013340.","journal-title":"J Pharmacol Exp Ther"},{"key":"6_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/187152706784111551","volume":"5","author":"P Sokoloff","year":"2006","unstructured":"Sokoloff P, Diaz J, Le Foll B, et al. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets. 2006;5:25\u201343.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"6_CR26","volume-title":"Psychopharmacology (Berl)","author":"R Zimnisky","year":"2012","unstructured":"Zimnisky R, Chang G, Gyerty\u00e1n I, Kiss B, Adham N, Schmauss C. Cariprazine, a dopamine D(3)- receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl). 2012 [Epub ahead of print]."},{"key":"6_CR27","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.neuint.2011.07.002","volume":"59","author":"I Gyerty\u00e1n","year":"2011","unstructured":"Gyerty\u00e1n I, Kiss B, S\u00e1ghy K, et al. Cariprazine (RGH-188), a potent D3\/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59:925\u2013935.","journal-title":"Neurochem Int"},{"key":"6_CR28","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1471-4159.2010.06848.x","volume":"114","author":"AL Auclair","year":"2010","unstructured":"Auclair AL, Cathala A, Sarrazin F, et al. The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity. J Neurochem. 2010;114:1323\u20131332.","journal-title":"J Neurochem"},{"key":"6_CR29","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00213-011-2247-y","volume":"216","author":"A Newman-Tancredi","year":"2011","unstructured":"Newman-Tancredi A, Kleven MS. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology (Berl). 2011;216:451\u2013473.","journal-title":"Psychopharmacology (Berl)"},{"key":"6_CR30","first-page":"802","volume":"11","author":"A Newman-Tancredi","year":"2010","unstructured":"Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs. 2010;11:802\u2013812.","journal-title":"Curr Opin Investig Drugs"},{"issue":"Suppl.1","key":"6_CR31","first-page":"154","volume":"35","author":"DB Keator","year":"2009","unstructured":"Keator DB, Mukherjee J, Preda A, et al. Dopamine D2 and D3 receptor occupancy of cariprazine in schizophrenic patients. Schizophr Bull. 2009;35(Suppl. 1):154.","journal-title":"Schizophr Bull"},{"issue":"Suppl.3","key":"6_CR32","doi-asserted-by":"publisher","first-page":"S316","DOI":"10.1016\/S0924-977X(09)70472-9","volume":"19","author":"S Potkin","year":"2009","unstructured":"Potkin S, Keator D, Mukherjee J, et al. Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients. Eur Neuropsychopharmacol. 2009;19(Suppl. 3):S316.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl.4","key":"6_CR33","doi-asserted-by":"publisher","first-page":"S451","DOI":"10.1016\/S0924-977X(07)70684-3","volume":"217","author":"GP Meszaros","year":"2007","unstructured":"Meszaros GP, Kapas M, Borsos M, et al. Pharmacokinetics of RGH-188, a new dopamine D3\/ D2 antagonist\/partial agonist atypical antipsychotic, in healthy subjects. Eur Neuropsychopharmacol. 2007;217(Suppl. 4):S451\u2013S452.","journal-title":"Eur Neuropsychopharmacol"},{"key":"6_CR34","unstructured":"Ereshefsky L, Gage A, Yu B, et al. Phase I study of RGH-188 in schizophrenic patients. Poster Presentation NR4-61, American Psychiatric Association 161st Annual Meeting; May 3\u20138, 2008; Washington, DC."},{"issue":"Suppl.4","key":"6_CR35","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0924-977X(08)70635-7","volume":"18","author":"M Kapas","year":"2008","unstructured":"Kapas M, Meszaros GP, Yu B, et al. Comparison of the pharmacokinetic behaviour of RGH-188 in schizophrenic patients and healthy volunteers. Eur Neuropsychopharmacol. 2008;18(Suppl. 4):433.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl.1","key":"6_CR36","first-page":"128","volume":"40","author":"N Kirschner","year":"2008","unstructured":"Kirschner N, Gemesi LI, Vastag M, et al. In vitro metabolism of RGH-188. Drug Metab Rev. 2008;40(Suppl. 1):128\u2013129.","journal-title":"Drug Metab Rev"},{"key":"6_CR37","unstructured":"Litman R, Papadakis K, Durgam S, Xie J. Use of cariprazine in the treatment of schizophrenia: a proof-of-concept trial. Poster Presentation 61, 60th Institute on Psychiatric Services of the American Psychiatric Association; October 2\u20135, 2008; Chicago, IL."},{"key":"6_CR38","unstructured":"Bose A, Li D, Migliore R, et al. The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia. Poster Presentation I-73, NCDEU 50th Annual Meeting; June 14\u201317, 2010; Boca Raton, FL."},{"key":"6_CR39","unstructured":"Forest Laboratories, Inc. and Gedeon Richter Plc. Announce Results from Two Positive Phase III Trials with the Investigational Antipsychotic Cariprazine for the Treatment of Schizophrenia [press release]. Forest Laboratories, Inc.; February 28 2012. Available at: http:\/\/news.frx.com\/press-release\/rd-news\/forest-laboratories-inc-and-gedeon-richter-plc-announce-results-two-positive-p. Accessed November 6 2012."},{"key":"6_CR40","unstructured":"Cariprazine Relative to Placebo in the Prevention of Relapse of Symptoms in Patients With Schizophrenia. Forest Laboratories, Inc. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01412060. Accessed November 6 2012."},{"key":"6_CR41","unstructured":"Cutler A, Bose A, Durgam S, et al. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week extension study. Poster Presentation NR6-50, American Psychiatric Association 165th Annual Meeting; May 5\u20139, 2012; Philadelphia, PA."},{"key":"6_CR42","unstructured":"Safety, pharmacokinetics and efficacy study of MP- 214 in patients with schizophrenia. Mitsubishi Tanabe Pharma Corporation. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00862992. Accessed November 6 2012."},{"key":"6_CR43","unstructured":"Geodon (ziprasidone) [product information]. Pfizer; revised October 2012. Available at: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=584. Accessed January 11 2013."},{"key":"6_CR44","unstructured":"Abilify (aripiprazole) [product information]. Otsuka Pharmaceutical Co.; revised February 2012. Available at: http:\/\/www.abilify.com\/pdf\/pi.aspx. Accessed November 12 2012."},{"key":"6_CR45","unstructured":"Fanapt (iloperidone) [product information]. Novartis Pharmaceuticals Corporation.; revised January 2012. Available at: http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/fanapt.pdf. Accessed January 15 2013."},{"key":"6_CR46","unstructured":"Saphris (asenapine) [product information]. Merck & Co.; revised October 2012. Available at: http:\/\/www.merck.com\/product\/usa\/pi_circulars\/s\/saphris\/saphris_pi.pdf. Accessed January 11 2013."},{"key":"6_CR47","unstructured":"Latuda (lurasidone) [product information]. Sunovion Pharmaceuticals Inc.; revised May 2012. Available at: http:\/\/latudahcp.com\/LatudaPrescribingInformation.pdf. Accessed September 5 2012."},{"key":"6_CR48","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s12325-012-0052-6","volume":"29","author":"L Citrome","year":"2012","unstructured":"Citrome L. Lurasidone in schizophrenia: new information about dosage and place in therapy. Adv Ther. 2012;29:815\u2013825.","journal-title":"Adv Ther"},{"key":"6_CR49","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2147\/nedt.2006.2.4.427","volume":"2","author":"L Citrome","year":"2006","unstructured":"Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat. 2006;2:427\u2013443.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"6_CR50","doi-asserted-by":"publisher","first-page":"617","DOI":"10.4088\/JCP.11m07530","volume":"73","author":"JM Kane","year":"2012","unstructured":"Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52- week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73:617\u2013624.","journal-title":"J Clin Psychiatry"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-013-0006-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-013-0006-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-013-0006-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-013-0006-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T13:48:30Z","timestamp":1714744110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-013-0006-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,28]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["6"],"URL":"https:\/\/doi.org\/10.1007\/s12325-013-0006-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,28]]},"assertion":[{"value":"13 December 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2013","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}